Antiendometrial antibodies in endometriosis measured by an enzyme-linked immunosorbent assay before and after treatment with danazol and nafarelin.
No previous study has investigated prospectively the quantitative effect of treatment on antiendometrial antibody levels in endometriosis. We measured antiendometrial antibody levels by an enzyme-linked immunosorbent assay in 35 women with laparoscopically proved endometriosis who were treated for 6 months with danazol (N = 11) or nafarelin (N = 24) in a randomized double-blind study. Levels before treatment were significantly higher than in a control group (P less than .001). Levels were lowered by treatment, but to a significant extent only in the nafarelin group (P less than .001) (danazol group: P = .091). Our data suggest that in relation to antiendometrial antibodies, nafarelin has a suppressive effect which has previously been ascribed only to danazol.
Kennedy
S H
SH
Nuffield Department of Obstetrics and Gynecology, University of Oxford, John Radcliffe Hospital, United Kingdom.
Starkey
P M
PM
Sargent
I L
IL
Hicks
B R
BR
Barlow
D H
DH
D000328:Adult; D001323:Autoantibodies / Q000032:analysis*; D003613:Danazol / Q000627:therapeutic use*; D004311:Double-Blind Method; D004715:Endometriosis / Q000188:drug therapy / Q000276:immunology*; D004717:Endometrium / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D015337:Multicenter Studies as Topic; D017274:Nafarelin; D010386:Pelvic Neoplasms / Q000188:drug therapy / Q000276:immunology*; D011245:Pregnadienes / Q000627:therapeutic use*; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic
D001323:Autoantibodies; D011245:Pregnadienes; D017274:Nafarelin; D007987:Gonadotropin-Releasing Hormone; D003613:Danazol